search button

Safety of tirofiban for patients with acute ischemic stroke in routine clinical practice

  • Authors:
    • Yuan‑Qun Zhu
    • Yan‑Jun Zhang
    • Hai‑Lin Ruan
    • Qing Liu
    • Qin Zhan
    • Qiong Li

  • View Affiliations

  • Published online on: May 15, 2015     https://doi.org/10.3892/etm.2015.2495
  • Pages: 169-174
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to investigate the safety of tirofiban alone and in combination with various treatments in acute ischemic stroke (AIS). A total of 120 patients with AIS were included in the study, and these patients were divided into three treatment groups: Group A (tirofiban alone, n=68), group B (tirofiban plus thrombolytic therapy, n=26), and group C (tirofiban as a ‘bridging therapy’, n=26). Risk factors, stroke severity, initial imaging, treatment regimens, complications and long‑term outcomes were analyzed. In total, eight patients (6.7%) [six patients (23.1%) in group B and two patients (7.7%) in group C] had hemorrhage during or subsequent to treatment. Sixteen patients (six in group A, eight in group B and two in group C) succumbed during the hospital admission period. The mortality rate was 13.3% (8.8% for group A, 30.7% for group B and 7.7% for group C) in the acute phase. A favorable outcome (modified Rankin Scale score, 0‑2) in the first three months after stroke was only observed in 43.3% of patients (44.1% in group A, 46.7% in group B and 36.4% in group C). The mean Barthel index was 72.3 in group A, 84.4 in group B and 56.8 in group C (total patient population, 71.0). The results of the present study have shown that stroke treatment with tirofiban is safe in AIS. A large randomized controlled trial in the future is required to decrease the incidence of the minor bleeding complications associated with tirofiban therapy.
View Figures
View References

Related Articles

Journal Cover

July-2015
Volume 10 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.7
  • Ranked Medicine Research and Experimental
    (total number of cites)
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Zhu YQ, Zhang YJ, Ruan HL, Liu Q, Zhan Q and Li Q: Safety of tirofiban for patients with acute ischemic stroke in routine clinical practice. Exp Ther Med 10: 169-174, 2015
APA
Zhu, Y., Zhang, Y., Ruan, H., Liu, Q., Zhan, Q., & Li, Q. (2015). Safety of tirofiban for patients with acute ischemic stroke in routine clinical practice. Experimental and Therapeutic Medicine, 10, 169-174. https://doi.org/10.3892/etm.2015.2495
MLA
Zhu, Y., Zhang, Y., Ruan, H., Liu, Q., Zhan, Q., Li, Q."Safety of tirofiban for patients with acute ischemic stroke in routine clinical practice". Experimental and Therapeutic Medicine 10.1 (2015): 169-174.
Chicago
Zhu, Y., Zhang, Y., Ruan, H., Liu, Q., Zhan, Q., Li, Q."Safety of tirofiban for patients with acute ischemic stroke in routine clinical practice". Experimental and Therapeutic Medicine 10, no. 1 (2015): 169-174. https://doi.org/10.3892/etm.2015.2495